Effectiveness of treatment for concussion-related convergence insufficiency: The CONCUSS study protocol for a randomized clinical trial

• Published in: PloS one 2024-11, Vol.19 (11), p.e0314027
• Main Authors: Alvarez, Tara L, Scheiman, Mitchell, Gohel, Suril, Hajebrahimi, Farzin, Noble, Melissa, Sangoi, Ayushi, Yaramothu, Chang, Master, Christina L, Goodman, Arlene
• Format: Article
• Language: English
• Subjects: Accommodation, Ocular - physiology; Adolescent; Adult; Analysis; Arm; Best practice; Brain; Brain Concussion - complications; Brain Concussion - physiopathology; Brain Concussion - therapy; Brain research; Child; Children; Clinical trials; Cognition; Concussion; Consent; Convergence; Convergence, Ocular - physiology; Design standards; Effectiveness; Evaluation; Eye movements; Female; Health aspects; Humans; Hypotheses; Longitudinal studies; Male; Medical imaging; Neuroimaging; Ocular Motility Disorders - etiology; Ocular Motility Disorders - physiopathology; Ocular Motility Disorders - therapy; Post-Concussion Syndrome - diagnosis; Post-Concussion Syndrome - therapy; Randomized Controlled Trials as Topic; Signs and symptoms; Teenagers; Therapy; Treatment Outcome; Vergence eye movements; Young Adult; Young adults
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0314027

To describe CONCUSS, a randomized clinical trial (RCT) designed to compare the following: the effectiveness of immediate office-based vergence/accommodative therapy with movement (OBVAM) to delayed OBVAM as treatments for concussion-related convergence insufficiency (CONC-CI) to understand the impact of time (watchful waiting), the effect of OBVAM dosage (12 versus 16 therapy sessions), and to investigate the underlying neuro-mechanisms of OBVAM on CONC-CI participants. CONCUSS is an RCT indexed on https://clinicaltrials.gov/study/NCT05262361 enrolling 100 participants aged 11-25 years with medically diagnosed concussion, persistent post-concussive symptoms 4-24 weeks post-injury, and symptomatic convergence insufficiency. Participants will receive standard concussion care and will be randomized to either immediate OBVAM or delayed (by six weeks) OBVAM. At the Outcome 1 examination (week 7), clinical assessments of success as determined by changes in the near point of convergence (NPC), positive fusional vergence (PFV), and symptoms will be compared between the two treatment groups. After the Outcome 1 visit, those in the delayed group receive 16 visits of OBVAM, while those in the immediate OBVAM group receive four more therapy visits. Outcome 2 assessment will be used to compare both groups after participants receive 16 sessions of OBVAM. The primary measure is the between-group differences of the composite change in the NPC and PFV at the Outcome 1 visit. Secondary outcome measures include individual clinical measures, objective eye-tracking parameters, and functional brain imaging. Major features of the study design include formal definitions of conditions and outcomes, standardized diagnostic and treatment protocols, a delayed treatment arm, masked outcome examinations, and the incorporation of objective eye movement recording and brain imaging as outcome measures. CONCUSS will establish best practices in the clinical care of CONC-CI. The objective eye movement and brain imaging, correlated with the clinical signs and symptoms, will determine the neuro-mechanisms of OBVAM on CONC-CI.